So, assuming 2% growth, Gilead is slightly undervalued. In fact, Gilead appears valued for 0% growth. Actually, this may be a ...

Gilead Sciences has bolstered its position in the ... $225 million upfront plus a $100 million equity investment, and a partnership with Refuge Biotech on a gene editing platform designed to ...

Gilead Sciences (NasdaqGS:GILD) recently experienced a significant price movement, rising 24% in the last quarter. This ...

Gilead Sciences sets aside $200 million for a potential settlement over its HIV drug promotional speaker program amid federal ...

FOSTER CITY, Calif. & BALLERUP, Denmark, January 11, 2025--Gilead Sciences, Inc. (Nasdaq: GILD) and LEO Pharma today announced a strategic partnership to accelerate the development and commerciali ...

After Gilead Sciences' lenacapavir made waves with stellar clinical results as a twice-yearly HIV prevention candidate, the drug has shown promise being dosed even further apart at only once a year.

About Gilead HIV Gilead Sciences, Inc. is a biopharmaceutical ... needs of people affected by HIV around the world. Through partnerships, collaborations and charitable giving, the company also ...

YANKCOM Partnership purchased a new stake in shares of Gilead Sciences during the 4th quarter worth approximately $28,000. Decker Retirement Planning Inc. purchased a new stake in shares of Gilead ...

Phase 1 Data Indicate Potential for Use of Once-Yearly Lenacapavir for HIV Prevention, with Plans to Launch a Phase 3 Trial in 2H 2025 – ...